Rakovina Therapeutics’ private placement fuels DNA-damage response therapies

Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company pioneering innovative cancer therapies through advancements in DNA-damage response technologies, has successfully closed an oversubscribed private placement valued at $3 million. This funding represents a critical step in accelerating its AI-driven drug development pipeline.

The private placement included the issuance of 50 million units priced at $0.06 per unit. Each unit comprises one common share and one purchase warrant, allowing investors to acquire additional shares at $0.10 each within 24 months. The company retains the right to accelerate warrant exercise if its stock price surpasses $0.30 for 20 consecutive trading days.

Expanding Investor Confidence

The oversubscribed private placement demonstrates heightened investor confidence in Rakovina’s approach to DNA-damage response therapies. Executive Chairman Jeffrey Bacha emphasised that the robust investor participation highlights both the transformative potential of the company’s innovative cancer therapies and the expertise of its research team. Proceeds from this funding round will expedite the discovery and optimisation of AI-driven drug development initiatives, derived from its proprietary Deep Docking and Variational AI platforms.

In compliance with TSX Venture Exchange guidelines, Rakovina paid cash finder’s fees amounting to $180,841 and issued 3,021,872 finder’s warrants under terms identical to those of the private placement. All securities issued are subject to a four-month holding period.

Strengthening Drug Discovery Efforts

Rakovina Therapeutics remains steadfast in its mission to develop innovative cancer therapies targeting the DNA-damage response. The company aims to transition one or more AI-identified drug candidates into human clinical trials, while seeking regulatory approvals from Health Canada, the U.S. Food and Drug Administration, and other global regulatory authorities. This funding ensures that the company can further invest in AI-driven drug development processes, accelerating its goal of delivering effective solutions to cancer patients.

Strategic Investor Relations Partnership

To enhance market visibility and investor engagement, Rakovina has engaged Fairfax Partners Inc. as its investor relations partner. This new investor relations partnership involves a six-month programme, renewable for an additional term, focusing on inbound and outbound communications, digital marketing, and enhanced social media strategies. Fairfax will also support the creation of marketing materials and manage Rakovina’s communications during key investor-focused events.

Fairfax’s compensation includes a monthly fee of $5,000, a one-time setup fee of $15,000, and a $120,000 marketing budget. This investor relations partnership reflects Rakovina’s commitment to strengthening its outreach as the company progresses its strategic plans for 2025.

Expressing confidence in the partnership, Bacha stated that Fairfax’s expertise in investor relations and digital marketing would amplify Rakovina’s AI-driven drug development initiatives, increase shareholder value, and expand its institutional investor base.

Promising Outlook for 2025

With the successful completion of an oversubscribed private placement and the launch of a targeted investor relations partnership, Rakovina Therapeutics is poised for significant advancements in the coming year. Leveraging AI-driven drug development technologies, the company remains dedicated to creating innovative cancer therapies that deliver hope to patients and families worldwide.